Join to View Full Profile
1500 E Medical Center DrRogel Cancer CenterAnn Arbor, MI 48109
Dr. Alumkal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2002 - 2006
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1998 - 2002
Baylor College of MedicineClass of 1998
Certifications & Licensure
MI State Medical License 2019 - 2026
OR State Medical License 2006 - 2021
MD State Medical License 2002 - 2008
TX State Medical License 2000 - 2006
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Start of enrollment: 2014 Feb 05
- Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Start of enrollment: 2013 Mar 12
Publications & Presentations
PubMed
- LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer.Anbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, Eva Rodansky, Xiao-Ming Wang
Neoplasia. 2025-05-01 - Racial variation in the advanced prostate cancer genome.Emily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, Mikhail Dias, Adam Foye
Prostate Cancer and Prostatic Diseases. 2025-03-31 - A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigue.Caleb Mayer, Olivia Walch, Walter Dempsey, Kevin Hannay, Caroline Clingan
Cell Reports. Medicine. 2025-03-18
Journal Articles
- Maintenance and Pharmacologic Targeting of ROR1 Protein Levels via UHRF1 in T(1;19) Pre-B-ALLJoshi Alumkal, MD, Nature
Press Mentions
New Drug Target May Treat Aggressive Prostate Cancer EffectivelyApril 23rd, 2025- Panel Issues New Guidelines for Advanced Prostate CancerJanuary 13th, 2025
- Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
- Join now to see all
Grant Support
- Targeting Early Drivers of Prostate Cancer Lineage PlasticityUNIVERSITY OF MICHIGAN AT ANN ARBOR2025–2030
- Developing New Treatment Strategies for Neuroendocrine Prostate CancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2029
- Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain InhibitionUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
